A premature newborn born to an adolescent girl with acute Ebola virus disease and malaria survives in a resource ‐limited setting in an Ebola treatment unit in DR Congo: “A case report”
Key Clinical MessageIn the acute phase of Ebola virus disease (EVD) premature neonatal survival is extremely rare. High mortality is related to prematurity, neonatal complications of Ebola, and precarious conditions of neonatal care in underresourced ETUs. This is a case of preterm neonatal survival in the setting of acute maternal EVD infection.AbstractThis case describes rare preterm newborn survival in the setting of an Ebola treatment unit in Eastern DRC. The neonate was born vaginally to an acutely ill 17-year-old mother who was vaccinated against Ebola virus after being identified as a contact of her father, who was ...
Source: Clinical Case Reports - November 22, 2023 Category: General Medicine Authors: Prince Imani ‐Musimwa,
Emilie Grant,
Micheline Feza‐Malira,
Placide Mbala‐Kingebeni,
Gisèle Buhoro‐Baabo,
Espérence Zawadi‐Endanda,
Rigo Fraterne‐Muhayangabo,
Inès Claris‐Mwatsi,
Zacharie Tsongo‐Kibendelwa,
Olivier Nyakio‐Nge Tags: CASE REPORT Source Type: research
Examining the militarised hierarchy of Sierra Leone ’s Ebola response and implications for decision making during public health emergencies
In September, 2014, M édecins Sans Frontières (MSF) called for militarised assistance in response to the rapidly escalating West Africa Ebola Epidemic. Soon after, the United Kingdom deployed its military to Si... (Source: Globalization and Health)
Source: Globalization and Health - November 22, 2023 Category: International Medicine & Public Health Authors: Samuel T. Boland, Dina Balabanova and Susannah Mayhew Tags: Research Source Type: research
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response.TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430).CLINICALTRIALS: gov (NCT05064956).PMID:37981473 | DOI:10.1016/j.vaccine.2023.10.055 (Source: Vaccine)
Source: Vaccine - November 19, 2023 Category: Allergy & Immunology Authors: Edward Man-Lik Choi Ggayi Abu-Baker Mustapher Gloria Omosa-Manyonyi Julie Foster Zacchaeus Anywaine Michael Musila Mutua Philip Ayieko Tobias Vudriko Irene Ann Mwangi Yusupha Njie Kakande Ayoub Moses Mundia Muriuki Kambale Kasonia Nicholas Edward Connor N Source Type: research
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Biotechnol Adv. 2023 Nov 14:108283. doi: 10.1016/j.biotechadv.2023.108283. Online ahead of print.ABSTRACTA key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies targeting viral attachment and fusion glycoproteins that embellish viral particles. This observation has catalyzed the development of numerous viral glycoprotein mimetics as vaccines. Glycans can dominate the surface of viral glycoproteins and as such, the viral glycome can influence the antigenicity and immunogenicity of a candidate vaccine. In one extreme, glycans can form an integral part of epitopes targeted by neutralizing...
Source: Biotechnology Advances - November 16, 2023 Category: Biotechnology Authors: M L Newby J D Allen M Crispin Source Type: research
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Biotechnol Adv. 2023 Nov 14:108283. doi: 10.1016/j.biotechadv.2023.108283. Online ahead of print.ABSTRACTA key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies targeting viral attachment and fusion glycoproteins that embellish viral particles. This observation has catalyzed the development of numerous viral glycoprotein mimetics as vaccines. Glycans can dominate the surface of viral glycoproteins and as such, the viral glycome can influence the antigenicity and immunogenicity of a candidate vaccine. In one extreme, glycans can form an integral part of epitopes targeted by neutralizing...
Source: Biotechnology Advances - November 16, 2023 Category: Biotechnology Authors: M L Newby J D Allen M Crispin Source Type: research
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
Biotechnol Adv. 2023 Nov 14;70:108283. doi: 10.1016/j.biotechadv.2023.108283. Online ahead of print.ABSTRACTA key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies targeting viral attachment and fusion glycoproteins that embellish viral particles. This observation has catalyzed the development of numerous viral glycoprotein mimetics as vaccines. Glycans can dominate the surface of viral glycoproteins and as such, the viral glycome can influence the antigenicity and immunogenicity of a candidate vaccine. In one extreme, glycans can form an integral part of epitopes targeted by neutraliz...
Source: Biotechnology Advances - November 16, 2023 Category: Biotechnology Authors: Maddy L Newby Joel D Allen Max Crispin Source Type: research
Viral infections and pathogenesis of glaucoma: a comprehensive review
Clin Microbiol Rev. 2023 Nov 15:e0005723. doi: 10.1128/cmr.00057-23. Online ahead of print.ABSTRACTSUMMARYGlaucoma is a leading cause of irreversible blindness worldwide, caused by the gradual degeneration of retinal ganglion cells and their axons. While glaucoma is primarily considered a genetic and age-related disease, some inflammatory conditions, such as uveitis and viral-induced anterior segment inflammation, cause secondary or uveitic glaucoma. Viruses are predominant ocular pathogens and can impose both acute and chronic pathological insults to the human eye. Many viruses, including herpes simplex virus, varicella-z...
Source: Clinical Microbiology Reviews - November 15, 2023 Category: Microbiology Authors: Faraz Ahmad Nikhil Deshmukh Aaron Webel Sandra Johnson Ayman Suleiman Rajiv R Mohan Frederick Fraunfelder Pawan Kumar Singh Source Type: research
Viral infections and pathogenesis of glaucoma: a comprehensive review
Clin Microbiol Rev. 2023 Nov 15:e0005723. doi: 10.1128/cmr.00057-23. Online ahead of print.ABSTRACTSUMMARYGlaucoma is a leading cause of irreversible blindness worldwide, caused by the gradual degeneration of retinal ganglion cells and their axons. While glaucoma is primarily considered a genetic and age-related disease, some inflammatory conditions, such as uveitis and viral-induced anterior segment inflammation, cause secondary or uveitic glaucoma. Viruses are predominant ocular pathogens and can impose both acute and chronic pathological insults to the human eye. Many viruses, including herpes simplex virus, varicella-z...
Source: Herpes - November 15, 2023 Category: Infectious Diseases Authors: Faraz Ahmad Nikhil Deshmukh Aaron Webel Sandra Johnson Ayman Suleiman Rajiv R Mohan Frederick Fraunfelder Pawan Kumar Singh Source Type: research
Viral infections and pathogenesis of glaucoma: a comprehensive review
Clin Microbiol Rev. 2023 Nov 15:e0005723. doi: 10.1128/cmr.00057-23. Online ahead of print.ABSTRACTSUMMARYGlaucoma is a leading cause of irreversible blindness worldwide, caused by the gradual degeneration of retinal ganglion cells and their axons. While glaucoma is primarily considered a genetic and age-related disease, some inflammatory conditions, such as uveitis and viral-induced anterior segment inflammation, cause secondary or uveitic glaucoma. Viruses are predominant ocular pathogens and can impose both acute and chronic pathological insults to the human eye. Many viruses, including herpes simplex virus, varicella-z...
Source: Clinical Microbiology Reviews - November 15, 2023 Category: Microbiology Authors: Faraz Ahmad Nikhil Deshmukh Aaron Webel Sandra Johnson Ayman Suleiman Rajiv R Mohan Frederick Fraunfelder Pawan Kumar Singh Source Type: research
Viral infections and pathogenesis of glaucoma: a comprehensive review
Clin Microbiol Rev. 2023 Nov 15:e0005723. doi: 10.1128/cmr.00057-23. Online ahead of print.ABSTRACTSUMMARYGlaucoma is a leading cause of irreversible blindness worldwide, caused by the gradual degeneration of retinal ganglion cells and their axons. While glaucoma is primarily considered a genetic and age-related disease, some inflammatory conditions, such as uveitis and viral-induced anterior segment inflammation, cause secondary or uveitic glaucoma. Viruses are predominant ocular pathogens and can impose both acute and chronic pathological insults to the human eye. Many viruses, including herpes simplex virus, varicella-z...
Source: Clinical Microbiology Reviews - November 15, 2023 Category: Microbiology Authors: Faraz Ahmad Nikhil Deshmukh Aaron Webel Sandra Johnson Ayman Suleiman Rajiv R Mohan Frederick Fraunfelder Pawan Kumar Singh Source Type: research
Extracellular vesicle storm during the course of Ebola virus infection in primates
DiscussionThese results suggest a dynamic role for EVs in the modification of disease states in the context of EBOV. Overall, our work highlights the importance of viral factors, such as the GP, and host derived EVs in the inflammatory cascade and pathogenesis of EBOV, which can be collectively further exploited for novel antiviral development. (Source: Frontiers in cellular and infection microbiology)
Source: Frontiers in cellular and infection microbiology - November 15, 2023 Category: Microbiology Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
Designing Anti-Viral Vaccines that Harness Intrastructural Help from Prior BCG Vaccination
J Cell Immunol. 2023;5(4):97-102. doi: 10.33696/immunology.5.174.ABSTRACTVaccines are among the most effective tools for combatting the impact and spread of infectious diseases. However, the effectiveness of a vaccine can be diminished by vaccine inequality, particularly during severe outbreaks of infectious diseases in resource-poor areas. As seen in many developing countries that lack adequate healthcare infrastructure and economic resources, the acquisition and distribution of potentially life-saving vaccines may be limited, leading to prolonged suffering and increased deaths. To improve vaccine equity, vaccine design m...
Source: Cellular Immunology - November 10, 2023 Category: Allergy & Immunology Authors: Tony W Ng Steven A Porcelli Source Type: research
